Understanding blood inflammation in patients with atopic dermatitis
Dynamic Blood Inflammatory Profile in Atopic Dermatitis Patients
This study is trying to understand how the immune system reacts in the blood of people with moderate to severe atopic dermatitis by looking at blood samples from 100 patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice) |
| Trial ID | NCT05868824 on ClinicalTrials.gov |
What this trial studies
This study aims to characterize the immune response in the blood of patients with atopic dermatitis by collecting blood samples from 100 individuals at a referral center in Nice. The study will assess cytokine levels after stimulating whole blood with immune ligands to evaluate the immune response. The focus is on patients with moderate to severe atopic dermatitis who are eligible for systemic treatment. The findings could provide insights into the inflammatory processes associated with this condition.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with clinically diagnosed moderate to severe atopic dermatitis.
Not a fit: Patients who are pregnant, nursing, or have conditions that could impair evaluation or pose risks may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of atopic dermatitis through targeted therapies.
How similar studies have performed: While similar studies have explored immune responses in atopic dermatitis, this specific approach to dynamic blood inflammatory profiling is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged ≥ 18 years. * Patient with clinically diagnosed atopic dermatitis according to the criteria of Hanifin and Rajka. * Moderate to severe defined by an Investigator's Global Assessment ³3 and eligible to systemic treatment. * If the subject is a woman of childbearing potential, she has a negative urine pregnancy test. * Subject is non-pregnant, non-lactating and is not planning for pregnancy during the study period. * Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair his/her evaluation or which exposes the subject to an unacceptable risk by study participation. * Subject is able to comprehend and willing to sign an Informed Consent and/or Assent Form. * Affiliation to a social security scheme. * Signed informed consent Exclusion Criteria: * Vulnerable person: pregnant or nursing woman, minor, adult under guardianship or deprived of liberty * Patient with an infection * Patient with other systemic inflammatory disease * Patient with anti-inflammatory or immunosuppressive therapy * Patient with a contraindication to JAK inhibitors * Participants in other clinical therapeutic studies involving a drug that may interfere with the present evaluation
Where this trial is running
Nice
- Nice University Hospital — Nice, France (Recruiting)
Study contacts
- Study coordinator: HUBICHE Thomas
- Email: hubiche.t@chu-nice.fr
- Phone: 04 92 03 64 88
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.